Clinical Trial

Antibiotics in Pulmonary Mycobacterium Avium Complex Disease

Study Description

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

NTM therapy consists of a multi-drug macrolide based regimen for 18-24 months. Treated patients frequently experience debilitating side effects, and many patients delay the start of antibiotic treatment due to these risks. Common side effects include nausea, diarrhea, and fatigue, and rare but serious toxicities include ocular toxicity, hearing loss, and hematologic toxicity. To date, most of the evidence underlying the current treatment recommendations has come from observational studies in which either a macrolide has been combined with rifampin and ethambutol, or in some cases combined with ethambutol alone. The proposed study will answer whether a third drug is necessary or whether taking two drugs can increase tolerability without a substantial loss of efficacy.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Azithromycin

Azithromycin 500 MG Oral Tablet [ZITHROMAX]

Drug - Ethambutol

Ethambutol 25 mg/kg [MYAMBUTOL]

Drug - Rifampin

Rifampin 600 MG [RIFADIN]

Additional Information

Official Study Title

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

Clinical Trial ID

NCT03672630

ParticipAid ID

bW6Pva